TP53 in Acute Myeloid Leukemia: Evolving from Just Another Prognostic Marker to an Actionable Biomarker Informing Treatment
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136663
Abstract: Introduction Acute Myeloid Leukemia (AML) is a devastating disease with poor overall survival. Access to Precision Medicines is revolutionizing AML care and is driving an increase in Next Generation Sequencing (NGS) utilization to determine the… read more here.
Keywords: aml; diaceutics current; employment current; tp53 ... See more keywords
Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-138538
Abstract: Background: Relapse due to loss of the CD19 targeted epitope presents a therapeutic challenge of CD19 CAR-T therapy. These patients universally have poor outcomes. CD20 is a proven therapeutic target for B-Cell Non-Hodgkin Lymphomas (B-NHL),… read more here.
Keywords: biomedicine group; inc current; current employment; cellular biomedicine ... See more keywords
AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139655
Abstract: Upregulation of tumor CD47, the "don't eat me" signal, to evade immune surveillance is a common escape mechanism that evolves during cancer development, progression, and relapse. Previous studies have shown multiple myeloma (MM) cells leverage… read more here.
Keywords: employment current; oncology current; current employment; arch oncology ... See more keywords